Internal Medicine, Endocrinology, Diabetes, & Metabolism · St. Louis, MO
NPI
1407052996
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
10345 Watson Rd
St. Louis, MO, 63127
Phone (314) 384-3584
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
370 services
Medicare patients, 2024
73
Average age 67
Drug cost, 2024
$2.5M
1,887 prescriptions
Company payments, 2025
$125K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Megan D Wood was code 99214 (office e&m - established), 91 times for 49 patients. In total Megan D Wood billed 370 services in 29 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 91 | 49 | $89.83 | $8,174 |
| 99213 Office E&M - Established | Office | 45 | 32 | $67.01 | $3,016 |
| 99204 Office E&M - New | Office | 28 | 28 | $118.86 | $3,328 |
By year: 2022 $47K for 689 services; 2023 $35K for 538 services; 2024 $26K for 370 services.
Medicare prescription drug claims, 2024
In 2024, the drug Megan D Wood prescribed most often to Medicare patients was Metformin Hcl Er (Metformin Hcl), with 223 prescriptions and refills. In total Megan D Wood wrote 1,887 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metformin Hcl Er Metformin Hcl | 223 | 551 | 90 | $1,559 |
| Ozempic Semaglutide | 113 | 182 | 40 | $176K |
| Levothyroxine Sodium Generic | 107 | 298 | 54 | $978 |
| Farxiga Dapagliflozin Propanediol | 86 | 161 | 34 | $91K |
| Glimepiride Generic | 74 | 203 | 42 | $654 |
| Dexamethasone Generic | 70 | 70 | 48 | $60.11 |
| Atorvastatin Calcium Generic | 66 | 175 | 29 | $343 |
| Mounjaro Tirzepatide | 60 | 88 | 16 | $96K |
| Tresiba Flextouch U-200 Insulin Degludec | 54 | 117 | 23 | $56K |
| Rosuvastatin Calcium Generic | 53 | 151 | 26 | $533 |
| Korlym Mifepristone | 44 | 44 | Under 11 | $1.8M |
| Liothyronine Sodium Generic | 43 | 109 | 18 | $3,313 |
| Synthroid Levothyroxine Sodium | 41 | 115 | 23 | $4,045 |
| Unithroid Levothyroxine Sodium | 33 | 97 | 19 | $2,717 |
| Januvia Sitagliptin Phosphate | 29 | 51 | Under 11 | $28K |
Brand drugs: 777 claims; generic drugs: 1,010 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Megan D Wood $125K ($125K in general payments such as food, travel and fees) from 25 companies. The largest payer was Corcept Therapeutics with $121K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 146 | $121K |
| Insulet Corporation PODD | 8 | $2,172 |
| Xeris Pharmaceuticals, Inc. | 20 | $352 |
| Novo Nordisk Inc NVO | 16 | $255 |
| Recordati_rare_diseases_inc. | 13 | $250 |
| Abbvie Inc. ABBV | 18 | $207 |
| Esperion Therapeutics, Inc. ESPR | 6 | $115 |
| Lilly USA, LLC LLY | 5 | $109 |
| Verity Pharmaceuticals Inc. | 2 | $94.29 |
| Amneal Pharmaceuticals LLC AMRX | 5 | $89.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.